Top Tech Companies (124)
Don't see your company?
Create a company profile
Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and clinical testing, to microbiome analysis, and support on formulation development and certification. (www.sequential.bio) Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, Corundum Systems Biology, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo
Talent experts providing scalable, bespoke recruitment solutions for growing Life Science companies. We have experienced teams of recruiters who can advise and hire across all areas within: • Pharmaceutical • Biotechnology • CRO Services • Health Technology • Medical Devices Our services include contingent, retained, and embedded services, our own version of scaled RPO – suited to rapidly growing organisations. We also offer an investment platform, allowing fledgling SME’s access to our large network of qualified investors, VC’s and PE’s. We recruit extensively across APAC, EMEA & the USA and alongside our London HQ we have opened our West Coast office in June 2022, following Europe expansion to Germany and Switzerland later on this year. Our leadership and recruitment teams have seen the challenges growing Life Science organisations face, hence why we tailor each search to you and give valuable advice based on past experiences working with organisations that have faced your exact challenges. If you are interested to know what we can do for you - reach out and ask for our extensive list of case studies and testimonials from some of the most well-known and recognised companies in the world. We want to continue to make an impact on the incredible advancements within the Life Sciences industry and do this through connecting brilliant talent with brilliant companies
At AviadoBio our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
MicrofluidX presents the Cyto Engine, a unified bioreactor and data platform for cell and gene therapy research, development, and manufacturing
GlamorousAI is bringing drugs to every target though its AI-first SaaS platform for drug discovery, RosalindAI. RosalindAI advancing AI to address small, noisy and sparse data challenges with a technology validated experimentally in the lab.
CN Bio is a leading organ-on-a-chip (OOC) company that enables researchers to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® suite of microphysiological systems, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Intestine/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment and function of their human counterparts in vitro. The approach provides a viable alternative to animal models where translatability to humans is predicted to be poor and for testing advanced drug modalities where human-specific targets and pathways are required. They generate physiologically relevant, human-translatable, mechanistic data that enables researchers to progress only the safest and most efficacious drugs into in vivo animal studies and be better prepared for clinical trials. Please follow us for regular updates. It starts here.
Our team of scientists and product experts are on a mission: developing Sensory Intelligence to seamlessly anchor machines into physical reality. Exciting things are in the pipeline... Stay tuned! #SensoryIntelligence #FutureOfMachines
We are a biotech company developing microbiome-based female health products. Our patented bioactive intimate serum helps to fight bad bacteria for improved urinary tract and intimate health.
Ascend is an end-to-end gene therapy development partner with deep expertise in gene therapy development and commercialization. We offer unparalleled collaboration while working to develop your products from the bench through the clinic and beyond. Scientific innovation driven by quality and responsibility are at the core of our business. To set a new standard in the industry, we have invested in a world-class analytical toolkit within our flexible and scalable AAV platform of next-gen technologies, all built to find the perfect balance of yield and quality for each process. Let’s aim higher and develop the next wave of accessible life-saving therapies together!
At AviadoBio our mission is to potentially transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Wellcome supports science to solve the urgent health challenges facing everyone. We’re a global charitable foundation. And we want everyone to benefit from science’s potential to improve health and save lives. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, climate and health and infectious diseases. Ask us questions, comment on posts and share your thoughts with us. We want to spark conversations, inspire debate and create new collaborations. Find out more about Wellcome: https://wellcome.org/who-we-are
Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference. Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks, Ellipses Pharma aims to be the most direct route from the research laboratory to patients for cancer treatments. Clinical trials are the route to developing more cancer treatments. All too often they have become overly complex and expensive, slowing down the progress of new discoveries and new treatments for patients. We streamline the clinical trials process that so often inhibits the progress of new potential drugs with one overarching objective - making more treatments available to patients. Ellipses provides a permanent source of capital for the development of cancer assets via a scalable business model, and is able to conduct multiple oncology clinical trials in parallel. Supported by our Scientific Affairs Group which comprises many of the world's leading oncologists, Ellipses is taking a new, ambitious approach to significantly impact the cancer drug development market.
Cytiva, now with the life sciences business from Pall Corporation, is a global life sciences leader dedicated to helping customers discover and commercialize the next generation of therapeutics. Together, we bring dedicated technical expertise and a broad portfolio of tools and technologies that enable the development, manufacture, and delivery of transformative medicines to patients. Visit cytiva.com to learn more.
We’re a team made up of healthcare workers who’ve lived the struggles of temporary staffing. So we’re here to transform the way it’s managed once and for all, by unleashing the power of flexible working to solve the global healthcare workforce crisis. How do we do it? We combine our industry-leading technology with our extensive specialist expertise - to bring an entirely tailored service to each healthcare organisation and solve their unique challenges for good. With Patchwork, we go beyond simply achieving the obvious requirements of surging staff bank growth and fill rates, slashing agency spend, increasing patient safety and saving time. But what truly transforms our partner organisations is our first-hand healthcare experience and expertise, our genuine passion and tireless effort to create real change for the future. Let’s together unleash the power of flexible working
Detecting brain diseases radically early using the way you speak
Phycobloom is developing the next generation of algae for the future world.
ENBIOSIS Biosciences reaches deep into your inner world with microbiome analysis and offers you the key for a sustainable and healthy life
Zedsen’s proprietary, non-invasive sensor aims to change the current paradigm of health and oncological care for the better. We are committed to addressing the Institute for Healthcare Improvement’s “Triple Aim'' for optimising healthcare systems, by enhancing the quality of care, improving the health of the overall patient population, and decreasing the cost of healthcare per capita
Modern Synthesis is a London based biomaterial company connecting the dots between biology, material science and design to craft the next generation of biomaterials for the fashion industry
At Opvia, we empower R&D, manufacturing and quality management teams to build custom process operating systems that streamline their workflows and give them a competitive edge. We work with fast-growing startups and enterprises across a range of industries, including biotech, pharma, food and beverages, engineering and medical devices, to help them digitize their processes and bring innovative products to market faster. With our powerful tools and expert support, we give companies the freedom to create and deliver like never before.
